Second-line tenofovir alafenamide for children with HIV in Africa

Victor Musiime, Alexander J Szubert, Hilda A Mujuru, Cissy Kityo, Katja Doerholt, Shafic Makumbi, Veronica Mulenga, Wedu Ndebele, Mwate Mwamabazi, Helen McIlleron, Mutsa Bwakura-Dangarembizi, Eva Natukunda, Kyomuhendo Jovia Linda, Lara Monkiewicz, Monica Kapasa, Mary Nyathi, Bwendo Nduna, Annabelle South, Godfrey Musoro, Khozya Zyambo, Yingying Zhang, Simon Walker, Anna Turkova, A Sarah Walker, Alasdair Bamford, Diana M Gibb, CHAPAS-4 Trial Team
doi: https://doi.org/10.1101/2024.04.12.24304337

Article Information

doi 
https://doi.org/10.1101/2024.04.12.24304337
History 
  • April 21, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Victor Musiime, PhD1,2,
  2. Alexander J Szubert, MSc3,
  3. Hilda A Mujuru, MMed4,
  4. Cissy Kityo, Phd2,
  5. Katja Doerholt, MSc3,
  6. Shafic Makumbi, MPH5,
  7. Veronica Mulenga, MSc6,
  8. Wedu Ndebele, MD7,
  9. Mwate Mwamabazi, MMed8,
  10. Helen McIlleron, PhD9,
  11. Mutsa Bwakura-Dangarembizi, PhD4,10,
  12. Eva Natukunda, MMed2,
  13. Kyomuhendo Jovia Linda, MBChB11,
  14. Lara Monkiewicz, MSc3,
  15. Monica Kapasa, MD12,
  16. Mary Nyathi, MMed13,
  17. Bwendo Nduna, MMed10,
  18. Annabelle South, PhD3,
  19. Godfrey Musoro, MSc13,
  20. Khozya Zyambo, MMed12,
  21. Yingying Zhang, PhD14,
  22. Simon Walker, MSc14,
  23. Anna Turkova, MD3,
  24. A Sarah Walker, PhD3,
  25. Alasdair Bamford, PhD3,*,
  26. Diana M Gibb, MSc3,
  27. CHAPAS-4 Trial Team
  1. 1Makerere University, College of Health Sciences, School of Medicine, Department of Paediatrics and Child Health, Kampala, Uganda
  2. 2Joint Clinical Research Centre, Kampala, Uganda
  3. 3Medical Research Council Clinical Trials Unit at University College London, London, UK
  4. 4Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe
  5. 5Infectious Diseases Research Collaboration, Kampala, Uganda
  6. 6University of Zambia, School of Medicine, Lusaka, Zambia
  7. 7National University of Science and Technology (NUST), NUST Mpilo Hospital Complex, Bulawayo, Zimbabwe
  8. 8Arthur Davison Children’s Hospital, Ndola, Zambia
  9. 9University of Cape Town, Cape Town, South Africa
  10. 10University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe
  11. 11Joint Clinical Research Centre, Lubowa, Uganda
  12. 12University Teaching Hospitals Children’s Hospital, Zambia
  13. 13Mpilo Central Hospital, Bulawayo, Zimbabwe
  14. 14Centre for Health Economics, University of York, York, England, UK
  1. ↵*Corresponding author:
    Alasdair Bamford, Email: a.bamford{at}ucl.ac.uk; MRC Clinical Trials at University College London, 90 High Holborn, London WC1V 6LJ, United Kingdom

  1. # Contributed equally

Back to top
Posted April 21, 2024.
Download PDF

Supplementary Material

Data/Code
Email
Second-line tenofovir alafenamide for children with HIV in Africa
Victor Musiime, Alexander J Szubert, Hilda A Mujuru, Cissy Kityo, Katja Doerholt, Shafic Makumbi, Veronica Mulenga, Wedu Ndebele, Mwate Mwamabazi, Helen McIlleron, Mutsa Bwakura-Dangarembizi, Eva Natukunda, Kyomuhendo Jovia Linda, Lara Monkiewicz, Monica Kapasa, Mary Nyathi, Bwendo Nduna, Annabelle South, Godfrey Musoro, Khozya Zyambo, Yingying Zhang, Simon Walker, Anna Turkova, A Sarah Walker, Alasdair Bamford, Diana M Gibb, CHAPAS-4 Trial Team
medRxiv 2024.04.12.24304337; doi: https://doi.org/10.1101/2024.04.12.24304337
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area